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ventricular dilatation has increased within the last 15 years. 
In 1999, Jahns et al.  [5] described autoantibodies against 
the second extra-cellular loop of the beta-1-adrenergic re-
ceptor in patients with dilated cardiomyopathy. In an ex-
perimental proof-of-principle study, they immunised rats 
with a peptide against the second extra-cellular loop of the 
beta-1-adrenergic receptor, which resulted in the develop-
ment of antibodies against the peptide followed by pro-
gressive severe left ventricular dilatation and dysfunction 
after 9 months  [7] . Isogenic transfer of sera from animals 
positive for the antibodies resulted in a similar phenotype 
of left ventricular dilatation and dysfunction in the recipi-
ent animals within a similar time frame  [7] . At the func-
tional level, autoantibodies against the second extra-cel-
lular loop of the beta-1-adrenergic receptor are agonist-
stimulating  [5] and can induce apoptosis in isolated cardio-
myocytes from adult rats  [8] . In addition, autoantibodies 
against the second extra-cellular loop of the beta-1-adren-
ergic receptor are associated with serious ventricular ar-
rhythmias in patients with idiopathic dilated cardiomyop-
athy, and the presence of these autoantibodies indepen-
dently predicts sudden death  [9, 10] . These findings are 
confirmed by the results of Zhao et al.  [4]  that autoantibod-
ies against the second extra-cellular loop of the beta-1-ad-
renergic receptor are a risk factor for left ventricular dilata-
tion and that autoantibodies against the angiotensin II re-
ceptor type 1 were identified as risk markers for left 
ventricular dilatation in patients with type 2 diabetes  [4] .
 Zhao et al.  [4] also screened their patients for autoan-
tibodies against the second extra-cellular loop of the an-
 Type 2 diabetes is a major cause of illness and death. In 
the USA, for example, at least 65% of patients with type 2 
diabetes die of some form of heart disease or stroke  [1] . 
These patients are at increased risk for the presence of vul-
nerable coronary plaques but also left ventricular dilatation, 
which is the primary reason for sudden cardiac death (see 
 [2] and references therein). There is increasing evidence 
that autoimmunity may play an important role in the patho-
genesis and progression of left ventricular dilatation in type 
2 diabetes patients because many circulating cardiac auto-
antibodies have been found in those patients with myocar-
ditis and dilated cardiomyopathy (summarised in  [3] ).
 In this issue of  Cardiology , Zhao et al.  [4]  report on their 
study, in which they analysed the presence of two well-char-
acterised autoantibodies against G protein-coupled recep-
tors in cardiovascular disease, autoantibodies against the 
beta-1-adrenergic receptor and the angiotensin II receptor 
type 1. Both autoantibodies are directed at the second extra-
cellular loop of the respective receptor  [5, 6] . Zhao et al.  [4] 
recruited 179 type 2 diabetes patients with hypertension 
and 106 normotensive type 2 diabetes patients. Next, they 
determined autoantibodies against the second extra-cellu-
lar loops of the beta-1-adrenergic receptor and the angio-
tensin II receptor type 1 by ELISA. They found that the pa-
tients with hypertension were more often positive for these 
autoantibodies – 43.0% for the beta-1-adrenergic receptor 
and 44.1% for the angiotensin II receptor type 1 – than the 
normotensive patients (16.0 and 10.4%, respectively).
 Knowledge about the contribution of autoantibodies 
and the underlying mechanisms to the development of left 
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giotensin receptor type 1, which have been described for 
patients with malignant hypertension and pre-eclampsia 
 [6, 11] . Immunisation of rats with a peptide correspond-
ing to the second extra-cellular loop of the angiotensin 
receptor type 1 resulted in an increase in systolic blood 
pressure, heart rate and the ratio of heart weight to body 
weight compared to the control group  [12] . However, 
even though their involvement in hypertension is com-
monly accepted, the role of these autoantibodies in the 
development of cardiac arrhythmias is still unclear.
 The antibody-positive rates observed by Zhao et al.  [4] 
confirm previous published data for autoantibodies 
against the beta-1-adrenergic receptor in myocarditis and 
dilated cardiomyopathy  [3] . Depending on the sensitivity 
of the ELISA used, the rate can be up to 60% for patients 
with dilated cardiomyopathy  [13] . However, there is no 
experimental proof that these autoantibodies are actually 
responsible for or involved in the development of type 2 
diabetes, as autoantibodies against the beta-1-adrenergic 
receptor are associated with left ventricular dilatation and 
autoantibodies against the angiotensin II receptor type 1 
are associated with hypertension. Furthermore, the pos-
sibility that the autoantibodies were present before the 
onset of type 2 diabetes cannot be ruled out for the pa-
tients in the study by Zhao et al.  [4] .
 Zhao et al.  [4] treated their patients with metoprolol and 
valsartan for 7 months which resulted in a decreased left 
ventricular diameter in those patients identified as positive 
for the aforementioned autoantibodies, indicating that the 
detrimental effects of the autoantibodies may be reversed 
or slowed down. Although the autoantibody status was not 
analysed after the 7 months, this study is important be-
cause it shows that autoantibodies can serve as biomarkers 
for left ventricular dilatation and as risk markers for sud-
den death. The results infer that hypertensive patients with 
type 2 diabetes may benefit from pharmacological treat-
ment with beta-blockers and angiotensin II receptor block-
ers. Nonetheless, monitoring status for autoantibodies 
against the beta-1-adrenergic receptor and the angiotensin 
II receptor type 1 in hypertensive patients with type 2 dia-
betes could be an option for identifying those type 2 diabe-
tes patients with the highest risk for developing left ven-
tricular dilatation. This could indeed be helpful for provid-
ing an individual, target-oriented therapy for each patient.
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